SCHEMBL23459868

SCHEMBL23459868

CC12CC3(C)CC(C)(C1)CC(C(NC(=O)c1ccc4ccccc4c1OCc1ccc(C(F)(F)C(F)(F)F)cc1)C(=O)O)(C2)C3

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 6/20 0.50
▸ ALDH1A1 P00352 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KIFC1 Q9BW19 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MAOA P21397 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ PPARD Q03181 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ EZH2 Q15910 1/20 0.32
▸ SENP5 Q96HI0 1/20 0.32
▸ SENP2 Q9HC62 1/20 0.32
▸ SENP1 Q9P0U3 1/20 0.32
▸ ELANE P08246 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25598893 1.00 CXCR2 (0.50) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL25601618 0.93 CXCR2 (0.58) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23459904 0.93 CXCR2 (0.58) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23460204 0.89 CXCR2 (0.46) CXCR2MAOAPPARGPPARD
SCHEMBL23459893 0.87 CXCR2 (0.48) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL25601399 0.87 CXCR2 (0.48) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL38147003 0.84 CXCR2 (0.56) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23460921 0.84 CXCR2 (0.56) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23460922 0.84 CXCR2 (0.56) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23461082 0.82 CXCR2 (0.60) CXCR2ALDH1A1GAAMAPTKIFC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637414-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-26 — — US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113808-A1 CFTR-MODULATING ARYLAMIDES GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637414-B2 Arylamides and methods of use thereof CFTR, CLIC1, ABCC1 CXCR2 78/4885ALDH1A1 630/4885GAA 1236/4885
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885ALDH1A1 1072/4885GAA 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback